Omega-3 Fatty Acids during Pregnancy in Indigenous Australian Women of the Gomeroi Gaaynggal Cohort.
Natalie L GrayIsobel L StoodleyLisa G WoodClare Elizabeth CollinsLeanne J BrownKym M RaeKirsty G PringleTracy L Schumachernull The Gomeroi Gaaynggal Advisory CommitteePublished in: Nutrients (2023)
Higher dietary intakes of Omega-3 long-chain polyunsaturated fatty acids ( n -3 LC-PUFAs) have been linked to lower rates of preterm birth and preeclampsia. The aim of this analysis was to describe dietary intake and fractions of red blood cell (RBC) membrane LC-PUFAs during pregnancy in a cohort of Indigenous Australian women. Maternal dietary intake was assessed using two validated dietary assessment tools and quantified using the AUSNUT (Australian Food and Nutrient) 2011-2013 database. Analysis from a 3-month food frequency questionnaire indicated that 83% of this cohort met national n -3 LC-PUFA recommendations, with 59% meeting alpha-linolenic acid (ALA) recommendations. No nutritional supplements used by the women contained n -3 LC-PUFAs. Over 90% of women had no detectable level of ALA in their RBC membranes, and the median Omega-3 Index was 5.5%. This analysis appears to illustrate a decline in concentrations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) across gestation in women who had preterm birth. However, there was no visible trend in LC-PUFA fractions in women who experienced hypertension during pregnancy. Further research is needed to better understand the link between dietary intake of n -3 LC-PUFA-rich foods and the role of fatty acids in preterm birth and preeclampsia.
Keyphrases
- preterm birth
- pregnancy outcomes
- polycystic ovary syndrome
- fatty acid
- red blood cell
- gestational age
- low birth weight
- simultaneous determination
- cervical cancer screening
- mass spectrometry
- breast cancer risk
- early onset
- preterm infants
- liquid chromatography
- body mass index
- pregnant women
- emergency department
- weight loss
- clinical practice
- metabolic syndrome
- adipose tissue
- risk assessment
- tyrosine kinase